| Identification | More | [Name]
Beraprost sodium | [CAS]
88475-69-8 | [Synonyms]
2,3,3A-8B-TETRAHYDRO-2-HYDROXY-1-(3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-1H-CYCLOPENTA[B]BENZOFURAN-5-BUTANOIC ACID, SODIUM SALT
BERAPROST
BERAPROST SODIUM SALT
ML 1129
PROCYLIN
TRK 100
beraprostsodium
2,3,3a-8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoic acid, sodium salt
1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-, monosodium salt
Dorner
MDL 201129
Sodium 2,3,3a-8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta[b]benzofuran-5-butanoate
Befraprost | [Molecular Formula]
C24H29NaO5 | [MDL Number]
MFCD00911570 | [Molecular Weight]
420.47 | [MOL File]
88475-69-8.mol |
| Chemical Properties | Back Directory | [Melting point ]
204-206°C | [storage temp. ]
-20°C | [solubility ]
DMF:77.0(Max Conc. mg/mL);183.12(Max Conc. mM)
Ethanol:20.0(Max Conc. mg/mL);47.56(Max Conc. mM)
PBS (pH 7.2):19.0(Max Conc. mg/mL);45.19(Max Conc. mM) | [form ]
powder | [color ]
white to beige | [InChIKey]
YTCZZXIRLARSET-LIIFYGAANA-M | [SMILES]
[C@H]12[C@H](C[C@@H](O)[C@@H]1/C=C/[C@@H](O)C(C)CC#CC)OC1C(=CC=CC2=1)CCCC([O-])=O.[Na+] |&1:0,1,3,5,8,r| | [CAS DataBase Reference]
88475-69-8(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Beraprost sodium is a new, orally active antithrombotic epoprostenol analog introduced as a treatment for peripheral vascular disease, including Raynaud's syndrome and
Buerger's disease. The antiplatelet activity may be due to its elevation of cyclic AMP
in platelets which is achieved by activating adenylate cyclase in the platelet membrane,
followed by the inhibition ofCa++- influx and thromboxane A2 formation. | [Chemical Properties]
White Solid | [Originator]
Toray (Japan) | [Uses]
Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral). | [Definition]
ChEBI: Beraprost sodium is the organic sodium salt of beraprost. It is used in the treatment of chronic arterial occlusive disease and primary pulmonary hypertension in Japan. It has a role as an antihypertensive agent, a platelet aggregation inhibitor, a prostaglandin receptor agonist, a vasodilator agent and an anti-inflammatory agent. It contains a beraprost(1-). | [Brand name]
Dorner; Dorner;Procylin | [General Description]
Beraprost sodium is an orally active prostacyclin analog. | [Biochem/physiol Actions]
Beraprost sodium is used as a therapeutic agent for chronic artery obstructions or primary pulmonary hypertension. In individuals with coronary artery disease, beraprost sodium helps to reduce oxidative stress and developed forearm endothelium dependent vasodilation. | [Side effects]
Disease-related events had similar incidence in patients receiving beraprost and those receiving placebo. Drug-related adverse events like headache, flushing, jaw pain, and diarrhea were more common in patients treated with beraprost sodium and occurred mostly during the six-week titration period. The incidence was markedly reduced in the maintenance period. Six patients (9%) in the beraprost sodium group and two (3%) in the placebo group withdrew prematurely from the study because of adverse events. No clinically adverse changes in hematologic or biochemical variables were seen in the beraprost sodium group.
|
|
|